<DOC>
	<DOCNO>NCT01695954</DOCNO>
	<brief_summary>The main goal study determine take efavirenz affect level pitavastatin bloodstream drug take together see darunavir ritonavir affect level pitavastatin bloodstream . Secondary goal see take pitavastatin affect level blood efavirenz drug take together see take pitavastatin affect level blood darunavir .</brief_summary>
	<brief_title>Pharmacokinetic Study Pitavastatin Ritonavir-Boosted Darunavir Efavirenz</brief_title>
	<detailed_description>HIV infect person risk coronary heart disease due chronic inflammation associate virus , side effect antiretroviral ( ARV ) therapy cause elevate cholesterol , risk factor smoke , high blood pressure family history heart disease . The commonly prescribed ARVs treatment HIV efavirenz drug protease inhibitor ( PI ) class darunavir ritonavir . To treat elevated cholesterol patient infected HIV , guideline recommend use statin ( class lipid lower drug ) . PIs efavirenz increase level statins reduce level others bloodstream . Pitavastatin ( Livalo ) statin approve Food Drug Administration ( FDA ) treatment high cholesterol . In order able use pitavastatin safely HIV-infected patient take either darunavir ritonavir efavirenz , important study take pitavastatin darunavir ritonavir pitavastatin efavirenz affect level drug bloodstream . Twenty-eight participant enrol one two study arm : 14 Arm A 14 Arm B . Arm A : Participants start take pitavastatin 2 mg tablet every night bedtime . On day 4 participant come 14-hour pharmacokinetic ( PK ) overnight visit 9 tablespoon blood drawn . Participants return 12 hour last blood draw final blood draw . They stop take pitavastatin . Participants start take one efavirenz 600 mg tablet bedtime . On day 14 , participant come second 14-hour visit 9 tablespoon blood drawn . They return 12 hour last blood draw final blood draw . Participants start take pitavastatin efavirenz bedtime . On day 18 , participant come third 14-hour PK visit 9 tablespoon blood drawn . They return 12 hour last blood draw final blood draw . They stop take study drug either come receive final phone call day 25 . Arm B : Participants start take one pitavastatin 2 mg tablet every morning . On day 4 participant come 14-hour pharmacokinetic ( PK ) daytime visit 9 tablespoon blood drawn . Participants return 12 hour last blood draw final blood draw . They stop take pitavastatin . Participants start take darunavir 400 mg tablet ( 2 ) ritonavir 100 mg tablet ( 1 ) every morning . On day 14 , participant come second 14-hour visit 9 tablespoon blood drawn . They return 12 hour last blood draw final blood draw . Participants start take one pitavastatin 2mg tablet , two darunavir 400 mg tablet one ritonavir 100 mg tablet . On day 18 , participant come third 14-hour PK visit 9 tablespoon blood drawn . They return 12 hour last blood draw final blood draw . They stop take study drug either come receive final phone call day 25 .</detailed_description>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Pitavastatin</mesh_term>
	<criteria>Absence HIV1 infection document licensed ELISA test kit within 21 day prior study entry . Male female age 1860 year . Able willing provide inform consent . All men woman reproductive potential must practice adequate birth control prevent pregnancy start study completion study . Women childbearing potential must negative serum urine pregnancy test within 14 day prior study entry day entry . Hemoglobin &gt; 12.5 g/dL men ; &gt; 11.5 g/dL woman ; Absolute neutrophil count &gt; 1,500 cells/mm3 ; Platelet count &gt; 100,000 platelets/mm3 ; AST ( SGOT ) /ALT ( SGPT ) &lt; 1.5X ULN ; Creatinine &lt; 1.5 X ULN Subject within 20 % ( +/ ) ideal body weight must weigh least 50 kg Use illicit drug alcohol would interfere completion study . Pregnancy breastfeed . History chronic illness hypertension , coronary artery disease , arthritis , diabetes , chronic gastrointestinal condition might interfere drug absorption . Any medical condition , opinion investigator , would interfere subject ability participate protocol . Use prohibit protocolspecified drug , prescription overthecounter within 14 day prior study entry . Participation investigational drug study within 30 day prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>HIV</keyword>
	<keyword>Hyperlipidemia</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Statins</keyword>
	<keyword>Darunavir</keyword>
	<keyword>Efavirenz</keyword>
	<keyword>Pitavastatin</keyword>
</DOC>